Press Releases Kymera Therapeutics, Inc.

Equities

KYMR

US5015751044

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2026-02-06 pm EST			5-day change	1st Jan Change
79.59 ^USD	+4.81%		+9.49%	+2.29%

Jan. 29	Kymera Therapeutics Reports Dosing in Phase 2b Asthma Trial	MT
Jan. 29	Kymera Therapeutics announces first patient dosed in breadth phase 2b asthma clinical trial of KT-621, a first-in-class, oral Stat6 degrader	RE

Press Releases

Feb. 04	Kymera Therapeutics to Participate in Upcoming February Investor Conferences	AQ
Jan. 29	Kymera Therapeutics Announces First Patient Dosed in BREADTH Phase 2b Asthma Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader	AQ
Jan. 13	Kymera Therapeutics Outlines Key 2026 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs	AQ
Jan. 06	Kymera Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13	AQ
Dec. 11	Kymera Therapeutics Announces Closing of Upsized $602 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares	AQ
Dec. 11	Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Atopic Dermatitis	AQ
Dec. 09	Kymera Therapeutics Announces Pricing of Upsized $602 Million Public Offering	AQ
Dec. 08	Kymera Therapeutics Announces Proposed Public Offering	AQ
Dec. 08	Kymera Therapeutics to Announce KT-621 BroADen Phase 1b Atopic Dermatitis Trial Results on December 8, 2025	AQ
Dec. 08	Kymera Therapeutics : Corporate Presentation, December 2025	PU
Dec. 08	Kymera Therapeutics Announces Positive Results from BroADen Phase 1b Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader, in Patients with Moderate to Severe Atopic Dermatitis	AQ
Dec. 05	Kymera Therapeutics to Announce KT-621 BroADen Phase 1b Atopic Dermatitis Trial Results on December 8, 2025	AQ
Nov. 25	Kymera Therapeutics Announces First Patient Dosed in BROADEN2 Phase 2b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader	AQ
Nov. 24	Kymera Therapeutics to Participate in Upcoming December Investor Conferences	AQ
Nov. 04	Kymera Therapeutics : Corporate Presentation, November 2025	PU
Nov. 04	Kymera Therapeutics Announces Third Quarter 2025 Financial Results and Provides a Business Update	AQ
Nov. 03	Kymera Therapeutics to Participate in Upcoming November Investor Conferences	AQ
25-10-28	Kymera Therapeutics to Report Third Quarter 2025 Financial Results on November 4, 2025	AQ
25-10-27	Kymera Therapeutics Presents New Preclinical Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at the American College of Rheumatology Annual Meeting	AQ
25-10-01	Kymera Therapeutics : Corporate Presentation, October 2025	PU
25-09-17	Kymera Therapeutics Announces Late-Breaking Oral Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the European Academy of Dermatology & Venereology and European Respiratory Society Congresses	AQ
25-09-03	Kymera Therapeutics Appoints Brian Adams as Chief Legal Officer and Corporate Secretary	AQ
25-08-27	Kymera Therapeutics to Participate in Upcoming September Investor Conferences	AQ
25-08-11	Kymera Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Business Update	AQ
25-08-07	Kymera Therapeutics : Corporate Presentation, August 2025	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

Press Releases Kymera Therapeutics, Inc.

Equities

KYMR

US5015751044

Biotechnology & Medical Research

Press Releases

Filters